A Randomized, Open-label, Parallel Group, Multi-center Study to Investigate Pharmacodynamic Effects After Daily Administration of Vilaprisan or Ulipristal Acetate for 8-12 Weeks in Patients With Uterine Fibroids for Whom Hysterectomy is Planned
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Vilaprisan (Primary) ; Ulipristal
- Indications Uterine leiomyoma
- Focus Biomarker; Pharmacodynamics
- Sponsors Bayer
- 12 Oct 2020 Status changed from active, no longer recruiting to discontinued.
- 15 Sep 2020 Planned End Date changed from 15 Sep 2020 to 15 Oct 2020.
- 17 Aug 2020 Planned End Date changed from 13 Aug 2020 to 15 Sep 2020.